Pramlintide — EU research guide.
Pramlintide is a synthetic analogue of amylin, the pancreatic hormone that slows gastric emptying and blunts post-meal glucagon — the same target class as cagrilintide, but first to reach the clinic decades earlier.
What is Pramlintide?
Pramlintide mimics amylin, a hormone co-secreted with insulin that beta cells release after meals. It slows gastric emptying, reduces glucagon secretion and increases satiety — complementary to, rather than overlapping with, GLP-1 agonism.
Status and research context
Approved in the US as Symlin for insulin-treated diabetes since 2005, pramlintide was withdrawn from the US market by its manufacturer in the early 2020s for commercial reasons, not safety, and it never received EU marketing approval. Its mechanism directly informs newer, longer-acting amylin analogues such as cagrilintide and petrelintide, now in Phase 3 obesity trials.
EU legal status
Never approved in the EU and no longer commercially marketed in the US. Research-grade pramlintide is available from RUO peptide suppliers.
Molecular information
Pharmacokinetics
Amylin-class compounds across EU suppliers
COA-verified EU vendors · Updated monthly